Arcutis Biotherapeutics, Inc. (ARQT) Tops Q4 EPS by 19c

Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) reported Q4 EPS of ($0.09), $0.19 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $71.3 million versus the consensus estimate of $54.72 million.

For earnings history and earnings-related data on Arcutis Biotherapeutics, Inc. (ARQT) click here.

You May Also Be Interested In

• Morgan Stanley Starts Tier IV Inc (593A:JP) at Overweight
• UBS Upgrades Celestica (CLS) to Buy
• Nomura/Instinet Reiterates Buy Rating on Samsung Electronics Co Ltd. (005930:KS) (SSNLF)